neoaltto: her2/cep17 ratio as a predictive biomarker in her breast cancer
Published 1 year ago • 257 plays • Length 2:27Download video MP4
Download video MP3
Similar videos
-
1:52
tils as a prognostic biomarker for treatment de-escalation in her2-positive breast cancer
-
2:39
the role of biomarkers in guiding treatment for early-stage breast cancer
-
1:39
dr. hurvitz on the lack of predictive biomarkers in her2 breast cancer
-
1:11
the mimosa trial and a novel prognostic factor in breast cancer
-
0:50
what is her2 breast cancer? #shorts
-
3:54
biomarker analysis of the neoaltto trial provides oncofertility insight for younger breast cance...
-
2:32
neoadjuvant biomarker analysis of neorhea: palbociclib in er /her2- bc
-
0:49
dr. o’regan on prognostic value of pcr in her2 breast cancer
-
2:49
neratinib, trastuzumab fulvestrant for her2-mutant, hr , metastatic breast cancer
-
10:23
sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment o...
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
5:47
the meaning of residual disease in breast cancer
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen
-
2:14
survival in premenopausal hr /her2- breast cancer with micro-metastasis and 21-gene score
-
0:36
how is her2 positive breast cancer treated? #shorts
-
1:52:35
biomarkers in breast cancer current practices, opportunities and unmet needs
-
5:31
her2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
6:47
extended adjuvant therapy for her2-positive early breast cancer